Chronic inflammation and atherosclerosis;Chronische Entzündung und Atherosklerose

Deutsche Medizinische Wochenschrift

Volumn 138, Issue 37, 2013, Pages 1839-1844

  Von Hundelshausen, P ^a   Weber, C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; interleukin 1; rheumatoid arthritis; statins; TNF

Indexed keywords

ATHEROSCLEROSIS; CHRONIC INFLAMMATION; REVIEW;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CHRONIC DISEASE; HUMANS; INFLAMMATION;

EID: 84883514044     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0033-1349426     Document Type: Review

References (48)

1. Adinolfi L. E., Restivo L., Zampino R. et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis: 2012; 221 496 502
2. Alexander M. R., Moehle C. W., Johnson J. L. et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest: 2012; 122 70 79
3. Almalag H. M., Mangoni A. A., Crilly M. A. Methotrexate and risk of cardiovascular disease. The American journal of cardiology: 2012; 109 1383 1384
4. Anderson J. L. Infection, antibiotics, and atherothrombosis - end of the road or new beginnings? N Engl J Med: 2005; 352 1706 1709 (Pubitemid 40530238)
5. Boilard E., Nigrovic P. A., Larabee K. et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science: 2010; 327 580 583
6. Booth A. D., Jayne D. R., Kharbanda R. K. et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation: 2004; 109 1718 1723 (Pubitemid 38500672)
7. Chiang N., Fredman G., Backhed F. et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature: 2012; 484 524 528
8. Chiu J. J., Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev: 2011; 91 327 387
9. Choy E., Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Annals of the rheumatic diseases: 2009; 68 460 469
10. Cobb S., Anderson F., Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med: 1953; 249 553 556
11. Denny M. F., Thacker S., Mehta H. et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood: 2007; 110 2907 2915 (Pubitemid 350006944)
12. Dixon W. G., Watson K. D., Lunt M. et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis and rheumatism: 2007; 56 2905 2912 (Pubitemid 47502736)
13. Fardet L., Petersen I., Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. Bmj: 2012; 345 e4928
14. Fellstrom B. C., Jardine A. G., Schmieder R. E. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med: 2009; 360 1395 1407
15. Gawaz M., Langer H., May A. E. Platelets in inflammation and atherogenesis. J Clin Invest: 2005; 115 3378 3384 (Pubitemid 43121822)
16. Grinspoon S., Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med: 2005; 352 48 62 (Pubitemid 40075680)
17. Hak A. E., Karlson E. W., Feskanich D. et al. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arth Rheum: 2009; 61 1396 1402
18. Hall A. O., Beiting D. P., Tato C. et al. The cytokines interleukin 27 and interferon-gamma promote distinct Treg cell populations required to limit infection-induced pathology. Immunity: 2012; 37 511 523
19. Huo Y., Schober A., Forlow S. B. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med: 2003; 9 61 67 (Pubitemid 36098261)
20. Jacobsson L. T. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol: 2005; 32 1213 1218 (Pubitemid 40995372)
21. Kjekshus J., Apetrei E., Barrios V. et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med: 2007; 357 2248 2261 (Pubitemid 350190755)
22. Koenen R. R., von Hundelshausen P., Nesmelova I. V. et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med: 2009; 15 97 103
23. Kwon G. P., Schroeder J. L., Amar M. J. et al. Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Circulation: 2008; 117 2919 2927 (Pubitemid 351787076)
24. Landewe R. B., van den Borne B. E., Breedveld F. C. et al. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet: 2000; 355 1616 1617 (Pubitemid 30240511)
25. Leghmari K., Contreras X., Moureau C. et al. HIV-1 Tat protein induces TNF-alpha and IL-10 production by human macrophages: differential implication of PKC-betaII and -delta isozymes and MAP kinases ERK1/2 and p38. Cellular immunology: 2008; 254 46 55
26. Lood C., Amisten S., Gullstrand B. et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood: 2010; 116 1951 1957
27. Maki-Petaja K. M., Hall F. C., Booth A. D. et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation: 2006; 114 1185 1192 (Pubitemid 44386483)
28. Marchand F. J. Über Arteriosklerose (Atherosklerose). Verhandlungen der Kongresse für Innere Medizin; Leipzig: 1904
29. McCarey D. W., McInnes I. B., Madhok R. et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet: 2004; 363 2015 2021 (Pubitemid 38781100)
30. Nicholls S. J., Ballantyne C. M., Barter P. J. et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med: 2011; 365 2078 2087
31. Nie H., Zheng Y., Li R. et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat Med: 2013; 19 322 328
32. Ortega-Gomez A., Perretti M., Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol Med: 2013; DOI: 10.1002/emmm.201202382
33. Perk J., De Backer G., Gohlke H. et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J: 2012; 33 1635 1701
34. Ricciotti E., Yu Y., Grosser T. et al. COX-2, the dominant source of prostacyclin. Proc Natl Acad Sci U S A: 2013; 110 E183
35. Ridker P. M., Danielson E., Fonseca F. A. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet: 2009; 373 1175 1182
36. Ridker P. M., Howard C. P., Walter V. et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation: 2012; 126 2739 2748
37. Seshasai S. R., Wijesuriya S., Sivakumaran R. et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Archives of internal medicine: 2012; 172 209 216
38. Soehnlein O., Zernecke A., Eriksson E. E. et al. Neutrophil secretion products pave the way for inflammatory monocytes. Blood: 2008; 112 1461 1471
39. Solomon D. H., Karlson E. W., Rimm E. B. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation: 2003; 107 1303 1307 (Pubitemid 36314415)
40. Subramanian M., Thorp E., Hansson G. K. et al. Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J Clin Invest: 2013; 123 179 188
41. Thompson R. C., Allam A. H., Lombardi G. P. et al. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet: 2013; 381 1211 1222
42. Tyrrell P. N., Beyene J., Feldman B. M. et al. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol: 2010; 30 1014 1026
43. von Hundelshausen P., Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res: 2007; 100 27 40 (Pubitemid 46066771)
44. Wang H., Dwyer-Lindgren L., Lofgren K. T. et al. Age-specific and sex-specific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet: 2012; 380 2071 2094
45. Weber C., Meiler S., Doring Y. et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest: 2011; DOI: 10.1172/JCI44925
46. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med: 2011; 17 1410 1422
47. Yu Y., Ricciotti E., Scalia R. et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med: 2012; 4 132ra154
48. Zeng M. Y., Pham D., Bagaitkar J. et al. An efferocytosis-induced, IL-4-dependent macrophage-iNKT cell circuit suppresses sterile inflammation and is defective in murine CGD. Blood: 2013; 121 3473 3483